DHA supplementation for late onset Stargardt disease: NAT-3 study

BACKGROUND: We analyzed the effects of a docosahexaenoic acid (DHA) supplementation in patients affected with late onset Stargardt disease (STGD). METHODS: DHA (840 mg/day) was given to 20 STGD patients for six months. A complete ophthalmologic examination, including best-corrected visual acuity (BC...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Querques, Giuseppe, Benlian, Pascale, Chanu, Bernard, Leveziel, Nicolas, Coscas, Gabriel, Soubrane, Gisele, Souied, Eric H
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2010
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2909886/
https://ncbi.nlm.nih.gov/pubmed/20668719
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky